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American tegumentary leishmaniasis (ATL) is an infectious disease caused mostly by Leishmania
(Viannia) braziliensis in Southeast Brazil. The clinical manifestations are vast, ranging from asymptomatic
to severe mucosal leishmaniasis (ML). It has been suggested that variation of the pathogen does not fully
explain the response spectrum and the variability of clinical manifestations. Previous data have shown
that host genetics also play a role in disease outcome. Herein, we have tested the association of TNF,
IL10, IL12 and MIF single nucleotide polymorphisms (SNPs) using a case-control study design including
110 cutaneous leishmaniasis (CL) patients and 682 healthy subjects. The genotype–phenotype correla-
tion was also assessed using leishmania antigens to stimulate peripheral blood mononuclear cells
obtained from cured CL patients. Results demonstrated that theMIF 173C allele is associated with leish-
maniasis outcome and also with lower levels of MIF in culture supernatants. Also, the TNF 308AA geno-
type was statistically increased among leishmaniasis patients. The results showed here suggest that the
lower levels of MIF produced by MIF 173C carriers could inﬂuence the host–Leishmania interaction,
favoring infection and disease progression. On the other hand, high TNF levels can contribute to tissue
damage, consequently leading to skin lesions.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
American tegumentary leishmaniasis (ATL) is an infectious dis-
ease caused by parasites of the Leishmania genus, which are trans-
mitted by several species of sand ﬂies to either humans or different
species of wild or domestic animals [1,2]. In Brazil, the incidence of
ATL has increased over the past 20 years in virtually every state
[3,4]. Leishmania spp. is an obligatory intracellular parasite that in-
fects mainly macrophages [5]. This infection is characterized by a
broad clinical and immunopathological spectrum, ranging from
an asymptomatic infection with spontaneous healing to severe dis-
ease. The cutaneous leishmaniasis (CL) is the most frequent clinicalnseníase, Fundação Oswaldo
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sevier OA license.form and often tends to heal spontaneously, while mucosal leish-
maniasis (ML), observed in 3–5% of infected subjects, is the most
severe clinical manifestation [6].
Regarding the immunological response in the ATL, has been de-
scribed that the type 1 immune response prevail in CL andML, with
an exacerbated production of IFNc and TNF that fails to be modu-
lated either by IL-10, TGFb or by neutralizing antibodies to IL-12
and IL-15 [7,8]. Patients with ML produce higher levels of IFNc and
TNF than CL, so this exaggerated type 1 immune response is unable
to control the parasite and also contributes to pathological tissue
damage [8,9]. Curiously, ML patients present low IL-10 production
which in turn can contribute to the exacerbated inﬂammatory im-
mune response [8,10]. In this context, macrophagemigration inhib-
itory factor (MIF) is a pleiotropic cytokine produced by the pituitary
gland andmultiple cell types, that exhibits a broad range of immune
and inﬂammatory activities, including the induction of cytokines
such as TNF, IFN-c, IL-1b, IL-12, IL-6 among others, and also can in-
crease the survival of macrophage [11–13], which might affect the
immune response to intracellular pathogens.
The exacerbated cytokine response in some individuals might
be genetic controlled. In the past few years, population-based
case-control studies used single nucleotide polymorphisms (SNPs)
in candidate genes as markers of susceptibility and severity of ATL
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may be, at least in part, inﬂuenced by the host immunogenetic
background [14–19].
The aim of this study was to replicate previous ﬁndings regard-
ing the association between the IL10 gene and ATL and also inves-
tigate whether additional cytokine genes involved in the control of
intracellular parasite infections (MIF, TNF and IL-12) as players of
susceptibility to cutaneous leishmaniasis in an endemic Brazilian
region. Here, the genetic association of these genes was evaluated
in a case-control study and the functional role of each gene was as-
sessed by determining the cytokine levels in of peripheral blood
cells cultures stimulated in vitro with leishmanial antigens.2. Material and methods
2.1. Subjects and study design
To assess the genetic susceptibility towards ATL, we used a
case-control design comparing CL cases with healthy controls
(HC). A total of 110 CL patients selected from areas endemic for
L. braziliensis infections were enrolled in this study (CL, 74 males
and 36 females; mean age = 38 ± 17 years old). The diagnostic cri-
teria were based on clinical, parasitological and immunological
parameters as described elsewhere [20]. Patients were reexamined
one year after the end of the therapy and were considered clinically
cured at the moment of this study. Of these, functional analysis
was carried out with 52 clinically cured CL patients for geno-
type–phenotype correlation. The HC group included a total of
682 subjects (359 males and 322 females; mean age = 33 ± 9.6 -
years old) recruited in the same geographic area as the cases (Rio
de Janeiro, Brazil). A second control group including 22 healthy
subjects (17 males and 5 females; mean age = 33 ± 10 years old)
was also selected for functional analyses. Written informed con-
sent was obtained from all individuals included in the study. The
present study was approved by the Ethical Committee for Human
Research of the Oswaldo Cruz Foundation, Brazilian Ministry of
Health (protocol number 577/09).
2.2. SNP genotyping
Genomic DNA was extracted from whole blood samples using
the salting out method. The polymorphism at IL12B +1188
(rs17875322) was genotyped by polymerase chain reaction (PCR)
and restriction fragment length polymorphism analysis, as de-
scribed elsewhere [21]. The IL10 819 (rs1800871), TNF 308
(rs1800629) and MIF 173 (rs755622) polymorphisms were geno-
typed by real-time PCR using ‘‘assay-by-design’’ TaqMan probes for
allelic discrimination according to manufacturer’s instructions
(Life Technologies, CA, USA). All reactions were performed in the
StepOne Plus instrument (Life Technologies).
2.3. Cell culture and IL-12p70, IL-10, MIF and TNF measurements
Peripheral blood mononuclear cells (PBMC) were obtained from
a total of 52 clinically cured CL patients and 22 HC using Ficoll-
Hypaque density centrifugation. Cell cultures (3  106 per well)
were stimulated in vitro with crude extract of L. braziliensis pro-
mastigote antigens (Lb-Ag, 50 lg/well) for 24 h for detection of
IL-12p70 and TNF and 72 h and 120 h for detection of IL-10 and
MIF, respectively, as previous described [20]. The levels of IL-
12p70, IL-10, MIF and TNF were measured in culture supernatants
by ELISA according to manufacturer’s instructions (R&D, Emery-
ville, CA, USA). Samples were tested in duplicate and concentra-
tions were measured using the SOFTmaxPRO 4.0 program (Life
Sciences Edition, Molecular Devices Corporation, USA). Assaysensitivity ranged from 15.62 to 1000 pg/mL for IL-12p70 and
TNF, and 31.25 to 2000 pg/mL for IL-10 and MIF.
2.4. Statistical analyses
The genotype and allele frequencies of the IL12B +1188A>C, IL10
819C>T, MIF 173G>C and TNF 308G>A SNPs were determined
by direct counting and a v2-test was applied to determine if the
observed frequencies conformed to the expected under Hardy–
Weinberg Equilibrium (HWE). The frequencies of each genotype,
allele and minor allele carriers in cases and controls were com-
pared by logistic regression models with adjustment for the non-
genetic covariate sex. A Cochran–Armitage trend test was applied
to assess allele dose effects. Odds ratios (ORs) were used as the
point estimates of risk and were calculated along with their 95%
conﬁdence intervals (CIs). All analyses were performed using the
statistical software R for Windows version 2.9.2 (R Development
Core Team, 2008) [22] with the packages ‘‘genetics’’ and ‘‘coin’’. Re-
sults obtained from quantitative variables were analyzed by One-
way Analysis of Variance (ANOVA) with Tukey-Kramer post-test,
using GraphPad Prism version 4.00 for Windows (GraphPad Soft-
ware, San Diego, CA, USA).3. Results
In total, 110 CL patients and 682 HC were genotyped. The geno-
typic, allelic and minor allele carrier frequencies are shown in Ta-
ble 1 along with the results of the logistic regression models. None
of the SNPs deviated from HWE in both populations (cases and
controls) tested.
As observed in Table 1, the MIF 173C carriers (CG + CC geno-
types) had a higher risk of developing CL (adjusted OR = 1.79;
p = 0.008). Furthermore, the risk estimates of GC and CC genotypes
(adjusted OR = 1.54 and 3.43, respectively) suggested an allele dose
effect, which was supported by the Cochran–Armitage trend test
(p = 0.001). For the TNF 308G/A SNP, the AA genotype was signif-
icantly increased among CL patients (6%) as compared to controls
(2%). The IL10 and IL12B SNPs were not associated to CL outcome
(Table 1).
Subsequently, the functional relevance of these SNPs was inves-
tigated by comparing the in vitro production of cytokines (IL-
12p70, IL-10, MIF and TNF) in PBMCs cultures of CL patients and
HC grouped according to their genotypes. The patient group pro-
duced higher levels of all cytokines tested when compared to con-
trols (Fig. 1). The secretion levels of IL-12p70 in the control group
were not quantiﬁed because it was below of the minimum levels of
assay detection (31.25 pg/mL). After stratiﬁcation of patients
according to their genotypes no differences were observed for IL-
10, IL-12p70, TNF and MIF secretion in leishmania stimulated
PBMC cultures. However, among controls the 173C carriers pro-
duced lower levels of MIF when compared to non-carriers
(4.3 ± 4.4 ng/mL vs. 14.5 ± 7.7 ng/mL; p = 0.01).4. Discussion
This study set out to investigate the effects of cytokine polymor-
phisms on leishmaniasis outcome. We ﬁrst selected the IL10 gene,
which had been previously found to be associated with leishman-
iasis and other infections [23,17] and also tested other candidate
genes such asMIF, IL12 and TNF due to their association with other
infectious diseases caused by intracellular pathogens [24–32].
The present study using a sample from Southern Brazil did not
replicate the association of the IL10 819C>T SNP which had been
previously described in the Northeast [17]. The present data indi-
cates that IL-10 is neither associated with cutaneous leishmaniasis
Table 1
Genotypic and allelic frequencies for the IL10 819C>T, IL12+1188 A>C, MIF 173G>C and TNF 308G>A SNPs in CL patients and HC.
SNP Genotype/allele Patients* Healthy controls* OR (95%CI; p-value) OR(95%CI; p-value)**
IL-10 CC 40 (0.38) 237 (0.42) Reference Reference
819C>T CT 54 (0.51) 248 (0.43) 1.29 (0.82–2.01; 0.26) 1.25 (0.80–1.97; 0.31)
TT 12 (0.11) 86 (0.15) 0.82 (0.41–1.64; 0.58) 0.77 (0.38–1.55; 0.47)
Total 106 571
C* 134 (0.63) 722 (0.63) Reference Reference
T 78 (0.37) 420 (0.37) 1.00 (0.65–1.53; 0.99) 0.97 (0.62–1.49; 0.89)
T carriers 66 (0.62) 334 (0.58) 1.17 (0.76–1.79; 0.46) 1.13 (0.73–1.73; 0.56)
IL-12 AA 58 (0.57) 381 (0.56) Reference Reference
+1188A>C AC 34 (0.34) 252 (0.37) 0.88 (0.56–1.39; 0.60) 0.87 (0.55–1.37; 0.56)
CC 9 (0.09) 49 (0.07) 1.20 (0.56–2.58; 0.62) 1.20 (0.55–2.58; 0.63)
Total 101 682
A* 150 (0.74) 1014 (0.74) Reference Reference
C 52 (0.26) 350 (0.26) 1.00 (0.62–1.61; 0.98) 0.99 (0.61–1.60; 0.98)
C carriers 43 (0.43) 602 (0.44) 0.93 (0.61–1.43; 0.76) 0.92 (0.60–1.41; 0.72)
MIF GG 47 (0.50) 389 (0.64) Reference Reference
173G>C GC 35 (0.37) 186 (0.31) 1.55 (0.97–2.49; 0.06) 1.54 (0.96–2.47; 0.07)
CC 12 (0.13) 30 (0.05) 3.31 (1.58–6.90; 0.001) 3.43 (1.64–7.20; 0.001)
Total 94 605 (p = 0.005)*** (p = 0.005)***
G* 129 (0.69) 964 (0.80) Reference Reference
C 59 (0.31) 246 (0.20) 1.79 (1.11–2.89; 0.01) 1.80 (1.11–2.91; 0.01)
C carriers 47 (0.50) 216 (0.36) 1.80 (1.16–2.78; 0.008) 1.79 (1.15–2.78; 0.008)
TNF GG 80 (0.77) 501 (0.76) Reference Reference
308G>A GA 18 (0.17) 148 (0.22) 0.76 (0.44–1.31; 0.32) 0.75 (0.44–1.30; 0.32)
AA 6 (0.06) 12 (0.02) 3.13 (1.14–8.57; 0.02) 3.10 (1.12–8.53; 0.02)
Total 104 661
G* 178 (0.86) 1150 (0.87) Reference Reference
A 30 (0.14) 172 (0.13) 1.12 (0.62–2.03; 0.69) 1.12 (0.61–2.03; 0.70)
A carriers 24 (0.23) 160 (0.24) 0.93 (0.57–1.53; 0.80) 0.93 (0.57–1.52; 0.79)
* Results are shown as total counts (frequency).
** Results adjusted for the covariate sex.
*** Overall p-values for genotype comparisons (2 degrees of freedom). CI: conﬁdence interval, SNP: single nucleotide polymorphism.
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Fig. 1. Leishmania induced-cytokine production according to genotypes. Peripheral blood mononuclear cells (PBMCs) of cutaneous leishmaniasis patients and healthy
controls according to different genotypes were cultured with Leishmania antigens and supernatants were collected after 72-h for IL-10 quantiﬁcation (A), after 24-h for IL-
12p70 quantiﬁcation (B) and after 120-h for TNF (C) and MIF (D) quantiﬁcation by ELISA. Results are shown for each sample (pg/mL or ng/mL). Each bar represent mean and
SEM of each group.
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between different L. braziliensis strains and different host genetic
backgrounds may lead to distinct ﬁnal outcomes.When candidate genes were tested, the genetic epidemiological
and functional analysis of the IL12 +1188A>C SNP did not show any
association with leishmaniasis, although patients presented a
C. de Jesus Fernandes Covas et al. / Cytokine 61 (2013) 168–172 171heterogeneous production of IL-12 with high and low producers
that did not cluster according to +1188A>C genotypes. A very inter-
esting result was the association of the TNF 308AA genotype with
cutaneous leishmaniasis. Functional analysis suggests that TNF
308A carriers secrete subtly higher amounts of TNF, although this
data did not show statistical signiﬁcance. Due to the low frequency
of the AA genotype, it is still unclear as to how 308AA individuals
respond to Leishmania antigens. It has been shown that TNF has a
broad range of functions, both in the resistance or immunopathol-
ogy of several infectious diseases, such as Chagas disease, leprosy,
malaria and tuberculosis [33,34,31,35–37]. In ATL, exacerbated
levels of TNF were correlated with extensive tissue damage among
mucosal leishmaniasis (ML) patients, the most severe form of ATL
[38,8,39,40]. Additionally, it was documented that carriers of this
allele produce higher levels of TNF protein, although results are
still controversial [41,42]. TNF 308A have been systematically
associated with autoimmune, metabolic, infectious and neurode-
generative diseases [43,44]. We can, therefore, hypothesize that
TNF 308AA carriers are high producers of TNF in leishmaniasis.
In this situation, strong localized secretion of TNF in 308AA indi-
viduals could be deleterious, since high TNF levels would be medi-
ating immunopathology, tissue damage and, consequently, disease
outcome.
The macrophage migration inhibitory factor (MIF) has been
described as an important component of the host antimicrobial
response and promotes the activation and secretion of pro-
inﬂammatory cytokines, including IFNc and TNF, by immune cells
[45,12]. MIF also increases macrophage survival through inhibition
of P53 activity, thus reducing activation-induced apoptosis [13],
which might affect the immune response to intracellular
pathogens.
For leishmaniasis, a study by Satoskar et al. [46] showed that
MIF gene-deﬁcient mice (MIF/) were highly susceptible to
cutaneous Leishmania major infection, developing severe skin le-
sions late after infection exhibiting greater parasite burdens than
wild-type (WT) mice. Curiously, similar proliferative responses
and production of IL-4 and IFNc cytokines among T-cell from mice
(MIF/) and WT were observed. However, IFNc-stimulated mac-
rophages harvested from MIF/ mice had a defective parasite
clearance which was associated with low superoxide and nitric
oxide levels. This ﬁnding suggests that susceptibility to L. major
in MIF/ mice is due to an impaired macrophage leishmanicidal
activity rather than deregulation of Th1 and Th2 responses. Thus,
it is also possible that MIF has a similar biological function in
humans enhancing the activation of macrophages and contributing
for parasite clearance.
Genetic studies have associated the MIF 173C allele with in-
creased susceptibility to infections, [47] such as Chagas’ disease
[28], tuberculosis [48,26,30] and severe malaria [27,31]. Our data
corroborate these previous ﬁndings by showing that the MIF
173C allele is also associated with CL susceptibility. Thus, it is
appealing that MIF play an important role during the innate im-
mune response against intracellular pathogens. Nevertheless, data
regarding the functional inﬂuence of this SNP are still controver-
sial, with studies reporting lower levels of MIF mRNA or protein
among 173C carriers [27,49,47], while other authors showed
otherwise [50,51]. Here, our results showed that the MIF 173C al-
lele was able to induce less MIF secretion in cell culture superna-
tants of healthy controls stimulated with Leishmania antigens.
However, this effect was not observed when cells from CL clinical
cured subjects were investigated. Temple and coworkers [49]
found increased basal levels of MIF mRNA among MIF 173C
carriers, although cells stimulated in vitro did not induce different
levels of MIF irrespective the donor’s genotype. We hypothesize
that the patients already have a steady programmed cellular
response because of the previous development of leishmaniasisand, thus, the subtle effect of the 173C allele would not be able
to inﬂuence MIF secretion at this stage. In fact, previous reports
have showed that even years after cure, patients may continuously
produce high levels of cytokines such as IFNc [20], indicating that
epigenetic factors may alter the expression of cytokines for a
lifetime. Moreover, we cannot exclude the possibility of an interac-
tion between additional polymorphisms, such as the MIF
794CATT5-8 microsatellite polymorphism, which might play a
role in the regulation of MIF gene expression. Nevertheless, moder-
ate linkage disequilibrium (r2 = 0.5–0.7) has been demonstrated
between MIF 794 and 173 polymorphisms in different popula-
tions, and it is likely that, at least in part, 173G>C is a good genet-
ic tag of this region for the present study [48,52,53,27,47,51].
In summary, the genetic and biological data suggest that MIF
plays a role in the very early events of the L. braziliensis infection
by regulating its replication and controlling disease outcome. Our
data suggest that theMIF173C allele is associated with lower lev-
els of MIF, and this decreased production may be associated with
leishmaniasis susceptibility [54]. This deﬁcient production of MIF
may reﬂect the difﬁculty of these individuals to activate an inﬂam-
matory response, with increased release of TNF and IFN-c, macro-
phage activation, nitric oxide production and elimination of
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